
    
      This is a phase 1B/2 open-label, ascending single and repeat dose clinical trial designed to
      evaluate the safety and efficacy of Light-activated AU-011 for the treatment of subjects with
      small primary choroidal melanoma.

      Throughout the study, subjects will be monitored through medical and ophthalmic assessments.
      Subjects will be followed for a total of 2 years.
    
  